Daniel J. Landsburg
About
Daniel J. Landsburg is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics.
According to data from OpenAlex, Daniel J. Landsburg has authored 136 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Oncology, 80 papers in Pathology and Forensic Medicine and 44 papers in Genetics. Recurrent topics in Daniel J. Landsburg's work include Lymphoma Diagnosis and Treatment (80 papers), CAR-T cell therapy research (57 papers) and Chronic Lymphocytic Leukemia Research (44 papers). Daniel J. Landsburg is often cited by papers focused on Lymphoma Diagnosis and Treatment (80 papers), CAR-T cell therapy research (57 papers) and Chronic Lymphocytic Leukemia Research (44 papers). Daniel J. Landsburg collaborates with scholars based in United States, Canada and Switzerland. Daniel J. Landsburg's co-authors include Jakub Svoboda, Sunita D. Nasta, Stephen J. Schuster, Elise A. Chong, Simon F. Lacey, Anthony R. Mato, Carl H. June, J. Joseph Melenhorst, Bruce L. Levine and David L. Porter and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Daniel J. Landsburg
128 papers receiving 3.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Daniel J. Landsburg United States | 23 | 2.4k | 908 | 722 | 721 | 716 | 136 | 3.3k | ||
| Bianca Santomasso United States | 19 | 3.2k 1.3× | 309 0.3× | 779 1.1× | 764 1.1× | 683 1.0× | 46 | 3.7k | ||
| Jon Arnason United States | 27 | 1.6k 0.7× | 988 1.1× | 615 0.9× | 1.4k 1.9× | 307 0.4× | 120 | 3.2k | ||
| Bambi Grilley United States | 21 | 3.7k 1.5× | 365 0.4× | 1.2k 1.7× | 1.5k 2.1× | 1.5k 2.1× | 69 | 4.4k | ||
| Carlos A. Ramos United States | 35 | 4.3k 1.8× | 604 0.7× | 2.1k 2.9× | 2.0k 2.8× | 1.5k 2.0× | 107 | 6.2k | ||
| Karin Straathof United States | 23 | 3.6k 1.5× | 387 0.4× | 1.2k 1.7× | 1.9k 2.6× | 1.4k 1.9× | 38 | 4.6k | ||
| Daniel Li United States | 15 | 2.8k 1.2× | 182 0.2× | 748 1.0× | 614 0.9× | 814 1.1× | 24 | 3.3k | ||
| Constance M. Yuan United States | 31 | 4.2k 1.8× | 1.2k 1.3× | 1.5k 2.0× | 1.7k 2.3× | 1.2k 1.7× | 121 | 5.9k | ||
| Meng-Fen Wu United States | 24 | 1.9k 0.8× | 211 0.2× | 679 0.9× | 642 0.9× | 537 0.8× | 43 | 2.6k | ||
| Jennifer L. Brogdon United States | 18 | 2.1k 0.9× | 252 0.3× | 785 1.1× | 1.6k 2.2× | 418 0.6× | 30 | 3.2k | ||
| Carolina Berger United States | 28 | 3.0k 1.3× | 142 0.2× | 1.2k 1.7× | 1.5k 2.1× | 1.1k 1.6× | 49 | 3.9k |
Countries citing papers authored by Daniel J. Landsburg
Since
Specialization
Citations
This map shows the geographic impact of Daniel J. Landsburg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Landsburg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Landsburg more than expected).
Fields of papers citing papers by Daniel J. Landsburg
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Daniel J. Landsburg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Landsburg. The network helps show where Daniel J. Landsburg may publish in the future.
Co-authorship network of co-authors of Daniel J. Landsburg
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel J. Landsburg. A scholar is included among the top collaborators of Daniel J. Landsburg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel J. Landsburg. Daniel J. Landsburg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Nasta, Sunita D., Jakub Svoboda, Stefan K. Barta, et al.. (2025). Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy. Transplantation and Cellular Therapy. 31(4). 228–235.
2.
Landsburg, Daniel J., Matthew J. Frigault, S.R. Foley, et al.. (2025). Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. Journal for ImmunoTherapy of Cancer. 13(2). e009890–e009890.
3.
Sussman, Jonathan, Colin Thomas, Daniel J. Landsburg, et al.. (2025). Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. JAMA Dermatology. 161(6). 656–656.
4.
Dave, Nikita, A Watts, Michael Cook, et al.. (2025). Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma. PubMed. 2(3). 100102–100102.
5.
Chong, Elise A., Elise A. Chong, Sunita D. Nasta, et al.. (2024). Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma. Transplantation and Cellular Therapy. 30(7). 726.e1–726.e8.
6.
Landsburg, Daniel J., Richard T. Maziarz, Amy Moskop, et al.. (2024). Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry. Blood. 144(Supplement 1). 4398–4398.
7.
Rojek, Alexandra E., Nausheen Ahmed, Sairah Ahmed, et al.. (2024). CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium. Blood. 144(Supplement 1). 4503–4503.
8.
Landsburg, Daniel J.. (2024). Improving Cure Rates for Patients with Newly Diagnosed Large B-Cell Lymphomas: Targeted Therapies for High-Risk Pathologic Subgroups as Defined by Clinical Laboratory Testing. Cancers. 17(1). 18–18.
9.
Yegya‐Raman, Nikhil, Christopher M. Wright, Michael J. LaRiviere, et al.. (2023). Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy. Clinical and Translational Radiation Oncology. 39. 100587–100587.
10.
Tavakkoli, Montreh, Elise A. Chong, Marco Ruella, et al.. (2023). CD5 Expression in Mature T Cell Lymphoma. Blood. 142(Supplement 1). 6195–6195.
11.
Rastogi, Supriya, Daniel J. Lewis, Leah Cohen, et al.. (2023). Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T‐Cell Lymphoma. Dermatologic Therapy. 2023(1).
12.
Landsburg, Daniel J., Sunita D. Nasta, Jakub Svoboda, et al.. (2023). Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells. Transplantation and Cellular Therapy. 29(8). 495–503.
13.
Chong, Elise A., Cécile Alanio, Jakub Svoboda, et al.. (2021). Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood. 139(7). 1026–1038.
14.
Wright, Christopher M., Michael J. LaRiviere, Jonathan Baron, et al.. (2020). Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma. International Journal of Radiation Oncology*Biology*Physics. 108(1). 178–188.
15.
Hughes, Mitchell E., Daniel J. Landsburg, Daniel J. Rubin, et al.. (2019). Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use. Clinical Lymphoma Myeloma & Leukemia. 19(12). 791–798.
16.
Farhan, Ahmed, Elise A. Chong, Stephen J. Schuster, et al.. (2018). Bexarotene in Patients With Peripheral T-cell Lymphomas: Results of a Retrospective Study. Clinical Lymphoma Myeloma & Leukemia. 19(2). 109–115.
17.
Chong, Elise A., J. Joseph Melenhorst, Jakub Svoboda, et al.. (2017). Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy. Blood. 130. 4121–4121.
18.
Svoboda, Jakub, Daniel J. Landsburg, Sunita D. Nasta, et al.. (2017). Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial. Blood. 130. 191–191.
19.
Howlett, Christina, Sonya J. Snedecor, Daniel J. Landsburg, et al.. (2015). Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysis. British Journal of Haematology. 170(4). 504–514.
20.
Cairns, Tina M., Daniel J. Landsburg, J. Charles Whitbeck, Roselyn J. Eisenberg, & Gary H. Cohen. (2005). Contribution of cysteine residues to the structure and function of herpes simplex virus gH/gL. Virology. 332(2). 550–562.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Bianca Santomasso Breakdown of academic impact, for papers by Jon Arnason Breakdown of academic impact, for papers by Bambi Grilley Breakdown of academic impact, for papers by Carlos A. Ramos Breakdown of academic impact, for papers by Karin Straathof Breakdown of academic impact, for papers by Daniel Li Breakdown of academic impact, for papers by Constance M. Yuan Breakdown of academic impact, for papers by Meng-Fen Wu Breakdown of academic impact, for papers by Jennifer L. Brogdon Breakdown of academic impact, for papers by Carolina Berger